United States securities and exchange commission logo





                          February 1, 2021

       John Climaco
       Chief Executive Officer
       CNS Pharmaceuticals, Inc.
       2100 West Loop South, Suite 900
       Houston, Texas 77027

                                                        Re: CNS
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed January 27,
2021
                                                            File No. 333-252471

       Dear Mr. Climaco:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Tim
Buchmiller at (202) 551-3635 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Cavas S. Pavri, Esq.